US Patent Issued to INTREXON ACTOBIOTICS on July 15 for "Genetically modified bacteria stably expressing IL-10 and insulin" (Belgian Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,359,210, issued on July 15, was assigned to INTREXON ACTOBIOTICS N.V. (Zwijnaarde, Belgium).

"Genetically modified bacteria stably expressing IL-10 and insulin" was invented by Pieter Rottiers (De Pinte, Belgium) and Lothar Steidler (Lokeren, Belgium).

According to the abstract* released by the U.S. Patent & Trademark Office: "The current disclosure provides microorganisms, such as lactic acid bacteria (e.g., Lactococcus lactis) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a T1D-specific antigen (e.g., a proinsulin) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbia...